Publications

Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020

Nature cancer

Old drugs with new tricks.

01-02-2020

European journal of immunology

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

01-01-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019

Cancer research

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

01-06-2019

The Journal of experimental medicine

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

03-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018

Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018

Cancer research

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

01-08-2018

Cell reports

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

26-06-2018

Cell research

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

01-06-2018

Molecular cancer therapeutics

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

01-04-2018

Cell reports

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

17-10-2017

European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017

Stem cells (Dayton, Ohio)

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

01-01-2017

Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016

Methods in molecular biology (Clifton, N.J.)

Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform.

02-09-2016

Oncotarget

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

12-07-2016

Molecular cancer therapeutics

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

01-07-2016

Oncotarget

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

21-06-2016

Nature biotechnology

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

01-06-2016

Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016

Oncotarget

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

19-01-2016

Scientific reports

The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1.

01-10-2015

Cell reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

29-09-2015

Nucleic acids research

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.

20-04-2015

Bioscience reports

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.

16-04-2015

Cell research

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

01-04-2015

Oncogene

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

22-01-2015

Cell reports

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

20-11-2014

Proceedings of the National Academy of Sciences of the United States of America

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

21-10-2014

Molecular systems biology

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

01-07-2014

Cell reports

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

10-04-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

Molecular and cellular biology

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

01-08-2013

Cell

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

21-11-2012

Journal of cellular and molecular medicine

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

01-09-2012

Nature

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

26-01-2012

The Journal of experimental medicine

A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation.

19-12-2011

PloS one

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

08-10-2011

Cancer discovery

Functional subtyping of breast cancer.

01-08-2011

Cell

A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation.

15-04-2011

Cell cycle (Georgetown, Tex.)

Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.

01-02-2011

IDrugs : the investigational drugs journal

Using large-scale RNAi screens to identify novel drug targets for cancer.

01-11-2010

Future oncology (London, England)

Exploration of synthetic lethal interactions as cancer drug targets.

01-11-2010

Molecular cancer research : MCR

Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade.

01-04-2010

Clinical cancer research : an official journal of the American Association for Cancer Research

Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.

15-09-2009

Cancer cell

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

07-04-2009

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

Old drugs with new tricks.

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

TRIM28 is an Epigenetic Barrier to Induced Pluripotent Stem Cell Reprogramming.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation.

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.

A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality.

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling.

MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation.

The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence.

Functional subtyping of breast cancer.

A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation.

Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.

Using large-scale RNAi screens to identify novel drug targets for cancer.

Exploration of synthetic lethal interactions as cancer drug targets.

Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade.

Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

This site uses cookies